Predictive factors for responders to deucravacitinib treatment in patients with psoriasis

The tyrosine kinase 2 inhibitor deucravacitinib is therapeutically effective for psoriasis. However, predictive factors for high responses to deucravacitinib have not been examined in a real-world clinical study. Our study aimed to identify predictive factors for responders to deucravacitinib. Therefore, a retrospective study was conducted on 74 patients with psoriasis treated with deucravacitinib (6 mg/day) at week 16 of treatment from January 2023 to February 2024. Patients were classified into responders (achievers of a static Physician's Global Assessment [sPGA] of 0 or 1 with ≥2-point improvement from basal sPGA) and non-responders (non-achievers). We compared baseline values of clinical and laboratory indexes between responders and non-responders. Multivariate logistic regression analysis was used to identify variables predicting responders. Forty-one patients (55.4%) were considered as responders at week 16. Multivariate logistic regression analysis revealed that the response to deucravacitinib was associated with higher age (odds ratio [OR] 1.04; 95% confidence interval [CI] 1.01-1.08; p = 0.0222) and lower body mass index (BMI) (OR 0.825; 95% CI 0.713-0.955; p = 0.0101). Higher age and lower BMI may predict a higher response to deucravacitinib (6 mg/day) at week 16 of treatment.